Innovative Medicine

- In current clinical practice, there are no FDA-approved treatments for this life-threatening condition - FDA designation suggests potential use of ibrutinib beyond hematologic malignancies - The FDA also granted ibrutinib orphan drug designation for cGVHD

Largest QuickFire competition to date will award up to $500,000 in a research grant and entrance to Johnson & Johnson Innovation, JLABS, to promising transformational healthcare solution Challenge launched at 2016 BIO International Convention during the Bionic Innovation Forum

Other Presentations at American Diabetes Association Scientific Sessions® Show INVOKANA® Therapy also is Associated with Achieving Blood Glucose and Blood Pressure Treatment Goals

Combination of Canagliflozin and Phentermine Demonstrates Improvements in Weight Management in Overweight or Obese Patients without T2DM

- Data from Phase 3 MMY3003 (POLLUX) trial to be featured in the Presidential Symposium at the European Hematology Association (EHA) Annual Congress (Abstract LB2238) - Phase 3 MMY3004 (CASTOR) trial data will also be highlighted at EHA - Together, these results show the potential of daratumumab in combination with either a proteasome inhibitor or immunomodulatory agent

Sirukumab One-year Radiographic Data Show Significant Inhibition of Joint Destruction

As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.

Comparative Analyses with DPP-4 Inhibitors, Including Sitagliptin, and Findings on Use in Weight Management and Type 1 Diabetes Underscore Janssen Commitment to Improving Diabetes Management